Abstract: Background: In the last decade, the development of anti-inflammatory strategies emerged as new trend in cardiovascular (CV) pharmacotherapy. Anti-inflammatory properties have been previously identified in different classes of drugs used in primary cardiovascular (CV) prevention. However, the extent to which the modification of inflammatory profile contributes in determining CV outcome remains controversial. Methods: Focusing on potential beneficial effects in primary prevention, this narrative review provides a comprehensive and critical analysis of randomized clinical trials testing anti-inflammatory treatments in CV disease. Results: As upstream regulator of the hepatic production of C-reactive protein, TNF-α, interleukin (IL)-6 and IL-1 pathways early emerged as potential targets for CV prevention. More recently, additional strategies targeting lipoprotein-associated phospholipase A2, proprotein convertase subtilisin/kexin type 9, and intracellular pathways (such as p38 MAPK and different isoforms of NADPH oxidase) have been tested. Conclusion: Conflicting results emerged from clinical trials, emphasized the need to characterize the inflammatory profile of the patients, to minimize the heterogeneity of study populations and to clarify the true value of CRP as specific biomarker of atherosclerosis-related inflammation.

Targeting Inflammation in Primary Cardiovascular Prevention

CARBONE, FEDERICO;LIBERALE, LUCA;BONAVENTURA, ALDO;CEA, MICHELE;MONTECUCCO, FABRIZIO
2016-01-01

Abstract

Abstract: Background: In the last decade, the development of anti-inflammatory strategies emerged as new trend in cardiovascular (CV) pharmacotherapy. Anti-inflammatory properties have been previously identified in different classes of drugs used in primary cardiovascular (CV) prevention. However, the extent to which the modification of inflammatory profile contributes in determining CV outcome remains controversial. Methods: Focusing on potential beneficial effects in primary prevention, this narrative review provides a comprehensive and critical analysis of randomized clinical trials testing anti-inflammatory treatments in CV disease. Results: As upstream regulator of the hepatic production of C-reactive protein, TNF-α, interleukin (IL)-6 and IL-1 pathways early emerged as potential targets for CV prevention. More recently, additional strategies targeting lipoprotein-associated phospholipase A2, proprotein convertase subtilisin/kexin type 9, and intracellular pathways (such as p38 MAPK and different isoforms of NADPH oxidase) have been tested. Conclusion: Conflicting results emerged from clinical trials, emphasized the need to characterize the inflammatory profile of the patients, to minimize the heterogeneity of study populations and to clarify the true value of CRP as specific biomarker of atherosclerosis-related inflammation.
File in questo prodotto:
File Dimensione Formato  
Carbone-MS.pdf

accesso chiuso

Tipologia: Documento in versione editoriale
Dimensione 3.66 MB
Formato Adobe PDF
3.66 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/860460
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 22
social impact